Isolated Hepatitis B Core Antibody Status is not Associated with Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection

Audrey L L French, Anna Hotton, Mary Young, Marek Nowicki, Michael Augenbraun, Kathryn Anastos, Eric Carl Seaberg, William Rosenberg, Marion G G Peters

Research output: Contribution to journalArticle

Abstract

BACKGROUND:: Isolated hepatitis B core antibody (anti-HBc) is a common serologic finding in HIV-infected persons but the clinical significance is uncertain. We studied HIV/HCV infected women over time to determine if the trajectory of liver disease progression (LDP) is affected by isolated anti-HBc serologic status. METHODS:: We performed serial Enhanced Liver Fibrosis (ELF) markers on HIV/HCV coinfected women to assess LDP trajectory over time comparing women with isolated anti-HBc to women with either negative HB serologies, anti-HBs alone or anti-HBc and anti-HBs. ELF, a serum marker that combines direct markers of extracellular matrix remodeling and fibrosis, was performed on serum stored biannually. Women with at least 3 ELF determinations and persistent HCV RNA positivity were included. RESULTS:: 344 women, including 132 with isolated anti-HBc and 212 with other serologic findings were included. A median of 6 (IQR 5-7) biannual ELF values were available for each woman, totaling 2119 visits. ELF increased over time from a median of 9.07 for women with isolated anti-HBc and 9.10 for those without to 9.83 and 9.88 respectively with no difference in degree of change or slope in the mixed effect model including age, race, CD4 count, antiretroviral therapy (ART), drug and alcohol use. Factors independently associated with LDP were older age, lower CD4, ART non-use and Hispanic ethnicity. CONCLUSION:: Isolated anti-HBc serologic status was not associated with accelerated liver disease progression over a median of 9.5 years among HIV/HCV coinfected women.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - Feb 24 2016

Fingerprint

Hepatitis B Antibodies
Hepatitis C
Coinfection
Disease Progression
Liver Diseases
HIV
Liver Cirrhosis
Serology
CD4 Lymphocyte Count
Hispanic Americans
Extracellular Matrix
Fibrosis
Biomarkers
Alcohols
RNA
Drug Therapy

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Isolated Hepatitis B Core Antibody Status is not Associated with Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. / French, Audrey L L; Hotton, Anna; Young, Mary; Nowicki, Marek; Augenbraun, Michael; Anastos, Kathryn; Seaberg, Eric Carl; Rosenberg, William; Peters, Marion G G.

In: Journal of Acquired Immune Deficiency Syndromes, 24.02.2016.

Research output: Contribution to journalArticle

French, Audrey L L ; Hotton, Anna ; Young, Mary ; Nowicki, Marek ; Augenbraun, Michael ; Anastos, Kathryn ; Seaberg, Eric Carl ; Rosenberg, William ; Peters, Marion G G. / Isolated Hepatitis B Core Antibody Status is not Associated with Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. In: Journal of Acquired Immune Deficiency Syndromes. 2016.
@article{4acc590721554c82b39160d9ce573ebc,
title = "Isolated Hepatitis B Core Antibody Status is not Associated with Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection",
abstract = "BACKGROUND:: Isolated hepatitis B core antibody (anti-HBc) is a common serologic finding in HIV-infected persons but the clinical significance is uncertain. We studied HIV/HCV infected women over time to determine if the trajectory of liver disease progression (LDP) is affected by isolated anti-HBc serologic status. METHODS:: We performed serial Enhanced Liver Fibrosis (ELF) markers on HIV/HCV coinfected women to assess LDP trajectory over time comparing women with isolated anti-HBc to women with either negative HB serologies, anti-HBs alone or anti-HBc and anti-HBs. ELF, a serum marker that combines direct markers of extracellular matrix remodeling and fibrosis, was performed on serum stored biannually. Women with at least 3 ELF determinations and persistent HCV RNA positivity were included. RESULTS:: 344 women, including 132 with isolated anti-HBc and 212 with other serologic findings were included. A median of 6 (IQR 5-7) biannual ELF values were available for each woman, totaling 2119 visits. ELF increased over time from a median of 9.07 for women with isolated anti-HBc and 9.10 for those without to 9.83 and 9.88 respectively with no difference in degree of change or slope in the mixed effect model including age, race, CD4 count, antiretroviral therapy (ART), drug and alcohol use. Factors independently associated with LDP were older age, lower CD4, ART non-use and Hispanic ethnicity. CONCLUSION:: Isolated anti-HBc serologic status was not associated with accelerated liver disease progression over a median of 9.5 years among HIV/HCV coinfected women.",
author = "French, {Audrey L L} and Anna Hotton and Mary Young and Marek Nowicki and Michael Augenbraun and Kathryn Anastos and Seaberg, {Eric Carl} and William Rosenberg and Peters, {Marion G G}",
year = "2016",
month = "2",
day = "24",
doi = "10.1097/QAI.0000000000000969",
language = "English (US)",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Isolated Hepatitis B Core Antibody Status is not Associated with Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection

AU - French, Audrey L L

AU - Hotton, Anna

AU - Young, Mary

AU - Nowicki, Marek

AU - Augenbraun, Michael

AU - Anastos, Kathryn

AU - Seaberg, Eric Carl

AU - Rosenberg, William

AU - Peters, Marion G G

PY - 2016/2/24

Y1 - 2016/2/24

N2 - BACKGROUND:: Isolated hepatitis B core antibody (anti-HBc) is a common serologic finding in HIV-infected persons but the clinical significance is uncertain. We studied HIV/HCV infected women over time to determine if the trajectory of liver disease progression (LDP) is affected by isolated anti-HBc serologic status. METHODS:: We performed serial Enhanced Liver Fibrosis (ELF) markers on HIV/HCV coinfected women to assess LDP trajectory over time comparing women with isolated anti-HBc to women with either negative HB serologies, anti-HBs alone or anti-HBc and anti-HBs. ELF, a serum marker that combines direct markers of extracellular matrix remodeling and fibrosis, was performed on serum stored biannually. Women with at least 3 ELF determinations and persistent HCV RNA positivity were included. RESULTS:: 344 women, including 132 with isolated anti-HBc and 212 with other serologic findings were included. A median of 6 (IQR 5-7) biannual ELF values were available for each woman, totaling 2119 visits. ELF increased over time from a median of 9.07 for women with isolated anti-HBc and 9.10 for those without to 9.83 and 9.88 respectively with no difference in degree of change or slope in the mixed effect model including age, race, CD4 count, antiretroviral therapy (ART), drug and alcohol use. Factors independently associated with LDP were older age, lower CD4, ART non-use and Hispanic ethnicity. CONCLUSION:: Isolated anti-HBc serologic status was not associated with accelerated liver disease progression over a median of 9.5 years among HIV/HCV coinfected women.

AB - BACKGROUND:: Isolated hepatitis B core antibody (anti-HBc) is a common serologic finding in HIV-infected persons but the clinical significance is uncertain. We studied HIV/HCV infected women over time to determine if the trajectory of liver disease progression (LDP) is affected by isolated anti-HBc serologic status. METHODS:: We performed serial Enhanced Liver Fibrosis (ELF) markers on HIV/HCV coinfected women to assess LDP trajectory over time comparing women with isolated anti-HBc to women with either negative HB serologies, anti-HBs alone or anti-HBc and anti-HBs. ELF, a serum marker that combines direct markers of extracellular matrix remodeling and fibrosis, was performed on serum stored biannually. Women with at least 3 ELF determinations and persistent HCV RNA positivity were included. RESULTS:: 344 women, including 132 with isolated anti-HBc and 212 with other serologic findings were included. A median of 6 (IQR 5-7) biannual ELF values were available for each woman, totaling 2119 visits. ELF increased over time from a median of 9.07 for women with isolated anti-HBc and 9.10 for those without to 9.83 and 9.88 respectively with no difference in degree of change or slope in the mixed effect model including age, race, CD4 count, antiretroviral therapy (ART), drug and alcohol use. Factors independently associated with LDP were older age, lower CD4, ART non-use and Hispanic ethnicity. CONCLUSION:: Isolated anti-HBc serologic status was not associated with accelerated liver disease progression over a median of 9.5 years among HIV/HCV coinfected women.

UR - http://www.scopus.com/inward/record.url?scp=84959235549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959235549&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000969

DO - 10.1097/QAI.0000000000000969

M3 - Article

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

ER -